已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Prospective Analysis of Arteriovenous Fistula Performance in the Context of Competing Risks

医学 背景(考古学) 动静脉瘘 血液透析 观察研究 前瞻性队列研究 外科 内科学 古生物学 生物
作者
Anukul Ghimire,Anita Lloyd,Susan K. Szigety,José Luis Merino,Karim Alibhai,Gerrit B. Winkelaar,Robert R. Quinn,Marcello Tonelli
出处
期刊:Kidney360 [American Society of Nephrology (ASN)]
标识
DOI:10.34067/kid.0000000650
摘要

Background: Many patients with newly created arteriovenous fistulas (AVF) may die before the AVF is needed for hemodialysis. However, formal competing risks frameworks are rarely used to report AVF patency, which may lead to biased estimates. We sought to identify the proportion of newly created AVF experiencing primary non-function and to describe long-term patency using a competing risk framework. Methods: We did a prospective observational study in 257 adults with newly created AVF in Alberta, Canada. The primary outcome was primary non-function. Secondary outcomes included loss of primary-patency, loss of assisted primary-patency, and loss of secondary functional-patency. Results were presented using icon-array plots to form the basis for future decision aids. Results: Participants were 63.0% male with mean age 62.3 years and median follow-up of 18.5 months (range 0.02-180 months). Of 257 participants, 50 could not be assessed for function or primary non-function, usually due to death. Of the remaining 207, 102 (49.3%) had primary non-function, and function was ultimately established for 142 (68.6%). Thus, only 142 of the 257 participants (55.3%) ultimately used the AVF for hemodialysis. High rates of competing risks led to biased results from Kaplan-Meier analyses of lost patency. When accounting for competing risks, loss of primary-patency among AVF with established function was 36.6%, 65.5% and 66.2%, at 1y, 3y and 5y respectively. Conclusions: Only 55% of fistulas were ultimately used for hemodialysis when accounting for competing risks and primary non-function. These results and the icon-array plots may inform discussions surrounding vascular access options for patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
山水之乐发布了新的文献求助10
2秒前
Jared应助清秀茹嫣采纳,获得10
3秒前
Dolantin关注了科研通微信公众号
4秒前
我是老大应助迅速的萃采纳,获得10
5秒前
科研通AI6应助小嘉要减肥采纳,获得10
5秒前
石东明完成签到 ,获得积分10
6秒前
8秒前
洛七落完成签到 ,获得积分10
9秒前
和谐板栗完成签到 ,获得积分10
9秒前
合适熊猫完成签到 ,获得积分10
10秒前
11秒前
LLL发布了新的文献求助10
11秒前
chrisio应助mege采纳,获得10
11秒前
SiO2完成签到 ,获得积分10
12秒前
852应助醉熏的马里奥采纳,获得10
12秒前
zq发布了新的文献求助10
13秒前
13秒前
14秒前
franklin_fsz应助牛马采纳,获得30
14秒前
丘比特应助LLL采纳,获得100
19秒前
22秒前
22秒前
Skywalker完成签到,获得积分10
22秒前
Rainy完成签到,获得积分10
23秒前
在水一方应助William采纳,获得10
25秒前
山水之乐发布了新的文献求助10
27秒前
nxdsk发布了新的文献求助10
27秒前
姜姗完成签到 ,获得积分10
30秒前
嘟晨发布了新的文献求助10
31秒前
时尚的康乃馨完成签到 ,获得积分10
32秒前
wab完成签到,获得积分0
33秒前
33秒前
科研通AI6应助huhdcid采纳,获得10
34秒前
zyz完成签到 ,获得积分10
35秒前
吴梓填完成签到,获得积分10
35秒前
gengen应助酷炫的芷蕾采纳,获得10
35秒前
xiang发布了新的文献求助10
37秒前
淡然莞发布了新的文献求助10
37秒前
38秒前
以心换心的猴子完成签到,获得积分10
38秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Theoretical modelling of unbonded flexible pipe cross-sections 3000
List of 1,091 Public Pension Profiles by Region 1581
Encyclopedia of Agriculture and Food Systems Third Edition 1500
Minimizing the Effects of Phase Quantization Errors in an Electronically Scanned Array 1000
Specialist Periodical Reports - Organometallic Chemistry Organometallic Chemistry: Volume 46 1000
Current Trends in Drug Discovery, Development and Delivery (CTD4-2022) 800
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5533920
求助须知:如何正确求助?哪些是违规求助? 4622104
关于积分的说明 14581561
捐赠科研通 4562182
什么是DOI,文献DOI怎么找? 2499969
邀请新用户注册赠送积分活动 1479626
关于科研通互助平台的介绍 1450707